Risk factors for medication-related osteonecrosis of the jaw in patients receiving bisphosphonates and/or denosumab: a systematic review of the literature
- 29 June 2026
- journal article
- review article
- Published by Media Sphere Publishing Group in Russian Journal of Stomatology
- Vol. 19 (2) , 56-62
Abstract
Background. Medication-related osteonecrosis of the jaw (MRONJ) remains a rare but clinically relevant complication of antiresorptive treatment. Its risk is shaped by the interaction of drug exposure, oral inflammatory burden, and systemic comorbidity. Objective. To synthesize evidence on risk factors for MRONJ in patients receiving bisphosphonates and/or denosumab and to derive a practice-oriented prevention algorithm. Material and methods. A PRISMA 2020-oriented systematic review was conducted in PubMed/MEDLINE, Scopus, Web of Science, and eLIBRARY.ru, supplemented by CyberLeninka and hand-searching of reference lists. Guidelines, systematic reviews/meta-analyses, cohort studies, and case-control studies focused on adult patients receiving bisphosphonates and/or denosumab were eligible. Thirty-seven records, including 17 Russian VAK-indexed publications, were included in the qualitative synthesis. Results. The most consistent risk factors were oncology-dose exposure, parenteral high-dose regimens, treatment duration and cumulative exposure, sequential antiresorptive/antiangiogenic therapy, active oral inflammatory disease, tooth extraction and other invasive dental procedures, as well as diabetes, smoking, anemia, and long-term corticosteroid use. Evidence on age, sex, vascular factors, and individual laboratory markers remains heterogeneous. Conclusion. MRONJ risk is multifactorial. The most applicable preventive measures are pre-treatment dental optimization, risk stratification by indication and drug class, scheduled monitoring, and a standardized management algorithm for invasive dental care.Keywords
This publication has 25 references indexed in Scilit:
- Risk factors of medication-related osteonecrosis of the jaw: A clinical investigationJournal of Stomatology Oral and Maxillofacial Surgery, 2024
- A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with DenosumabCancer Medicine, 2023
- Prognostic Involvement of Lymph Node Density in Oral Squamous Cell Carcinoma. A New Predictive ModelJournal of Oral and Maxillofacial Surgery, 2022
- American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 UpdateJournal of Oral and Maxillofacial Surgery, 2022
- Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumabClinical Oral Investigations, 2021
- Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastasesCancer Treatment Reviews, 2018
- A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?Osteoporosis International, 2017
- The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk FactorsOral and Maxillofacial Surgery Clinics of North America, 2015
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International ConsensusJournal of Bone and Mineral Research, 2014
- Cochrane Database of Systematic ReviewsCochrane Database of Systematic Reviews, 2007